Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is a rapidly growing company with strong financials, boasting a 14% sequential growth in net sales and an increase in new prescribers for VYVGART. The ongoing PFS launch and indication expansion will continue to drive growth, along with pipeline products such as ARGX-121, adimanebart, and empasiprubart, which have all shown positive results in clinical trials. Collaborations with top pharmaceutical companies also provide validation for argenx's antibody technology and potential for future success. With a strong pipeline and ongoing expansion efforts, argenx is well-positioned for long-term success in the biopharmaceutical industry.

Bears say

argenx is experiencing success with the expansion of their lead product, VYVGART, for the treatment of rare autoimmune diseases. However, risks to their price target and rating include potential failure in clinical, regulatory, or commercial aspects for this product or their pipeline, which could impact their overall financial performance in the future. It will be important to closely monitor the data presented at upcoming medical meetings and the outcome of the PDUFA date for seronegative gMG, as well as any potential setbacks in their other development efforts, in forming a comprehensive outlook on the company's future prospects.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,027.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,027.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.